Actinogen Medical Ltd (AU:ACW) — Market Cap & Net Worth
Market Cap & Net Worth: Actinogen Medical Ltd (ACW)
Actinogen Medical Ltd (AU:ACW) has a market capitalization of $78.71 Million (AU$111.25 Million) as of June 21, 2026. Listed on the AU stock exchange, this Australia-based company holds position #20206 globally and #669 in its home market, demonstrating a 2.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Actinogen Medical Ltd's stock price AU$0.04 by its total outstanding shares 3178477638 (3.18 Billion). Review ACW total liabilities to assess the company's total debt and financial obligations.
Actinogen Medical Ltd Market Cap History: 2015 to 2026
Actinogen Medical Ltd's market capitalization history from 2015 to 2026. Data shows change from $129.09 Million to $78.71 Million (-4.23% CAGR).
Actinogen Medical Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Actinogen Medical Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
24.99x
Actinogen Medical Ltd's market cap is 24.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $152.48 Million | $3.95 Million | -$3.63 Million | 38.57x | N/A |
| 2017 | $86.81 Million | $1.42 Million | -$3.19 Million | 61.33x | N/A |
| 2018 | $95.36 Million | $3.30 Million | -$6.23 Million | 28.89x | N/A |
| 2019 | $76.24 Million | $4.86 Million | -$9.89 Million | 15.68x | N/A |
| 2020 | $45.43 Million | $3.52 Million | -$5.33 Million | 12.92x | N/A |
| 2021 | $345.67 Million | $1.98 Million | -$3.92 Million | 174.22x | N/A |
| 2022 | $216.13 Million | $3.64 Million | -$9.50 Million | 59.37x | N/A |
| 2023 | $49.48 Million | $4.89 Million | -$10.75 Million | 10.12x | N/A |
| 2024 | $56.22 Million | $9.93 Million | -$13.04 Million | 5.66x | N/A |
| 2025 | $137.19 Million | $5.49 Million | -$14.73 Million | 24.99x | N/A |
Competitor Companies of ACW by Market Capitalization
Companies near Actinogen Medical Ltd in the global market cap rankings as of June 21, 2026.
Key companies related to Actinogen Medical Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Actinogen Medical Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Actinogen Medical Ltd's market cap moved from $129.09 Million to $ 78.71 Million, with a yearly change of -4.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$78.71 Million | -42.62% |
| 2025 | AU$137.19 Million | +144.00% |
| 2024 | AU$56.22 Million | +13.64% |
| 2023 | AU$49.48 Million | -77.11% |
| 2022 | AU$216.13 Million | -37.48% |
| 2021 | AU$345.67 Million | +660.89% |
| 2020 | AU$45.43 Million | -40.41% |
| 2019 | AU$76.24 Million | -20.05% |
| 2018 | AU$95.36 Million | +9.84% |
| 2017 | AU$86.81 Million | -43.07% |
| 2016 | AU$152.48 Million | +18.12% |
| 2015 | AU$129.09 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Actinogen Medical Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $78.71 Million USD |
| MoneyControl | $78.71 Million USD |
| MarketWatch | $78.71 Million USD |
| marketcap.company | $78.71 Million USD |
| Reuters | $78.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Actinogen Medical Ltd
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more